



Advances in the Treatment of Schizophrenia

Guest Editors:

Prof. Dr. Adam M. Kaye

Department of Pharmacy
Practice, Thomas J. Long School
of Pharmacy and Health
Sciences, University of the
Pacific, Stockton, CA 95207, USA

Dr. Amber Edinoff

Department of Psychiatry and
Behavioral Medicine, LSU Health
Shreveport, Shreveport, LA
71103, USA

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

Dear Colleagues,

Schizophrenia remains one of the most serious clinical conditions. It is associated with a chronic relapsing course and pronounced cognitive dysfunction in a large proportion of patients, despite therapeutic advancements over the past few decades. This Special Issue will provide a review of recent and historical research in the field of schizophrenia pharmacology and therapeutics. Furthermore, this issue will consider the mechanisms underlying schizophrenia development and progression, symptomatic improvement, improving adherence to pharmacologic treatment and the treatment of side effects to allow personalized care.

Prof. Dr. Adam M. Kaye

Dr. Amber Edinoff

Guest Editors

